This study sought to determine genetics and oncology specialists’ views of integrating BRCA1 and BRCA2 testing in epithelial ovarian and breast cancer into routine practice.
Qualitative interviews were designed using the Consolidated Framework for Implementation Research. Questions included experiences or views of the BRCA testing processes, implementation needs of oncology health professionals, perceived challenges, and future ideas for interventions to integrate genetic testing into oncology.
Twenty-two participants were interviewed from twelve health organizations and four themes were identified: (1) embracing the shift to mainstream genetic testing, with the majority of participants viewing BRCA testing as clinically useful and routine use important for maintaining a patient centered process; (2) the need for communication networks and role delineation to integrate routine genetic testing; (3) factors that influence sustaining routine genetic testing, including ongoing training, resources and funding, real-world adaptation, system complexity, and champions; and (4) variation in system interventions for integrating routine genetic testing align to organizational context.
Findings illustrate the need for integrating genetic testing into routine oncology, and that adaptation of interventions and processes is essential to sustain a feasible model. An understanding of individual and organizational implementation factors will help to prepare for future integration of routine genetic testing in other cancers.
Subscribe to Journal
Get full journal access for 1 year
only $94.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654–2663.
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Version 2.2013 Accessed 15 February 2014. https://www.nccn.org/professionals/physician_gls/default.aspx.
Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, et al. Uptake of clinical genetic testing for ovarian cancer in Ontario: a population based study. Gynecol Oncol. 2009;112:68–72.
Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, et al. Evaluating women with ovarian cancer for BRCA and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115:945–952.
Petzel SV, Vogel RI, Bensend T, Leininger A, Argenta PA, Geller MA. Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic. J Genet Couns. 2013;22:662–673.
Demsky R, McCuaig J, Maganti M, Murphy KJ, Rosen B, Armel SR. Keeping it simple: genetics referrals for all invasive serous ovarian cancers. Gynaecol Oncol. 2013;130:329–333.
eviQ. Genetic testing for heritable mutations in the BRCA1 and BRCA2 genes. Sydney, Australia: Cancer Institute NSW; 2017. https://www.eviq.org.au/Protocol/tabid/66/id/620/Default.aspx?popup=1.
Petelin L, James PA, Trainer AH. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia. Intern Med J. 2018;48:1269–1272.
Medical Service Advisory Committee (MSAC). 1411.1 Genetic testing for hereditary mutations predisposing to cancer (breast and/or ovarian) (resubmission). 2017. http://www.msac.gov.au/internet/msac/publishing.nsf/content/1411.1-public.
Kirk J, Barlow-Stewart KK, Poplawski NK, Gleeson M, Tucker K, Friedlander M. Medicare-funded cancer genetic tests: a note of caution. Med J Aust. 2018;209:193–196.
George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, costeffective, patient-centred, routine genetic testing in ovarian cancer patients. Sci. Rep. 2016;6:1–8.
Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL. Implementing a quality improvement project for universal genetic testing in women with ovarian cancer. Gynecol Oncol. 2018;149:565–569.
Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017;145:130–136.
Nielsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10:53.
Damschroder L, Aron D, Keith R, Kirsh S, Alexander J, Lowery J. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.
Kirk MA, Kelley C, Yankey N, Birken SA, Abadie B, Damschroder L. A systematic review of the use of the Consolidated Framework for Implementation Research. Implement Sci. 2016;17:11:72.
Sandelowski M. Whatever happened to qualitative description?. Res Nurs Health. 2000;23:334–340.
Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27:237–246.
Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. 2nd ed. Thousand Oaks, CA: Sage; 1998.
Norquist BM, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–490.
Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, et al. The integration of BRCA testing into oncology clinics. Br J Nurs. 2016;25:690–694.
Hamilton AB, Oishi S, Yano EM, Gammage CE, Marshall NJ, Scheuner MT. Factors influencing organizational adoption and implementation of clinical genetic services. Genet Med. 2014;16:238–245.
Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M. Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care. Fam Cancer. 2019;18:293–301.
West KM, Burke W, Korngiebel DM. Identifying “ownership” through role descriptions to support implementing universal colorectal cancer tumor screening for Lynch syndrome. Genet Med. 2017;11:1236–1244.
Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009;10:489–495.
Manolio TA, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15:258–267.
Orlando LA, Sperber NR, Voils C, Nichols M, Myers RA, Wu R, et al. Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network’s Common Measures Working Group. Genet Med. 2018;20:655–663.
Duoma KFL, Smets EMA, Allain DC. Non-genetic health professionals’ attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer. Fam Cancer. 2016;15:341–350.
Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317:531–533.
Owusu Obeng A, Fei K, Levy KD, Elsey A,R, Pollin T,I, Ramirez AH, Weitzel K,W, Horowitz CR. Physician-reported benefits and barriers to clinical implementation of genomic medicine: a multi-site IGNITE Network survey. J Pers Med. 2018;8:24.
Williams MS. Early lessons from the implementation of genomic medicine programs. Annu Rev Genom Hum Genet. 2019;20:389–411.
Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058–1063.
Schneider JL, Davis J, Kauffman TL, Reiss JA, McGinley C, Arnold K, et al. Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet Med. 2016;18:152–161.
Jenkins J, Calzone KA, Caskey S, et al. Methods of genomic competency integration in practice. J Nurs Scholarsh. 2015;47:200–210.
Crawford JM, Bry L, Pfeifer J, Caughron SK, Black-Schaffer S, Kant JA, et al. The business of genomic testing: a survey of early adopters. Genet Med. 2014;12:954–961.
Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, et al. Randomized noninferiority trial of telephone delivery of BRCA1/2 genetic counseling compared with in-person counseling: 1-year follow up. J Clin Oncol. 2016;34:2914–2924.
Hilgart JS, Hayward JA, Coles B, Iredale R. Telegenetics: a systematic review of telemedicine in genetics services. Genet Med. 2012;14:765–776.
Lieberman S, Lahad A, Tomer A, Cohen C, Levy-Lahad E, Raz A. Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience. Genet Med. 2016;19:628–634.
Sie AS, Spruijt L, van Zelst-Stams WA, et al. DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. BMC Womens Health. 2012;12:12
Rabin B, Glasgow RE. An implementation science perspective on psychological science and cancer: what is known and opportunities for research, policy, and practice. Am Psychol. 2015;70:211–220.
This research was funded by a Cancer Council New South Wales PhD scholarship and by a Translational Cancer Research Network Clinical PhD Scholarship Top-up award, supported by the Cancer Institute NSW supporting R.O.S. in the completion of her PhD studies in the Faculty of Medicine and Health at the University of Sydney.
M.K., M.G., and K.M.T. received remunerations from AstraZeneca in the initial development of BRCA mainstreaming interventions for epithelial ovarian cancer. The other authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
O’Shea, R., Rankin, N.M., Kentwell, M. et al. How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens. Genet Med (2020). https://doi.org/10.1038/s41436-020-0838-x
- routine genetic testing
- interventions and implementation